Cancer Center Support Grant (CCSG)
- Institution
- SALK INSTITUTE FOR BIOLOGICAL STUDIES, CA
- Principal investigator
- Reuben Shaw
- Funding
- $3.0M
- Duration
- 1996–2029
Moonbase score
Still being scored
Abstract
The Salk Institute is rooted in the notion that exploring the very foundations of life will benefit all. As one of the first Basic Laboratory Cancer Centers to receive the NCI designation in 1973, the Salk Cancer Center (SCC) is a world leader in cancer research, continuing its tradition of pioneering foundational research in cancer biology, gene expression, epigenetics, DNA damage/repair, metabolism, and immunology, as well as training the future generation of cancer scientists. Our central mission is basic discovery — discovery that is the foundation for cancer prevention and therapeutics. The SCC has two Research Programs: Genome Stability, Epigenetics & Aging in Cancer; and Tumor Immunology, Metabolism & Therapeutics. The Programs are supported by seven highly innovative Shared Resources providing SCC members access to cutting-edge technologies, services, and expertise. A recent major restructuring has streamlined decision-making and made leadership more responsive. SCC’s Cancer Research Training and Education Coordination Core is part of the fabric of these efforts, creating a pipeline for the next generation of exceptional cancer scientists and leaders. Through five Strategic Goals, the SCC emphasizes collaborative and translational research while focusing on training the next generation of scientists.
LOADING MOONBASE SCORE
Questions for SALK INSTITUTE FOR BIOLOGICAL STUDIES
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Salk Institute for Biological StudiesNot yet scored
Pancreatitis-induced initiation of early onset pancreatic cancer
Reuben Shaw · $189K · 2025–2026
- NIH · Salk Institute for Biological StudiesNot yet scored
Project 3: The AMPK Autophagy Pathway as a Metabolic Liability in Pancratic Ductal Adenocarcinoma
Reuben Shaw · $467K · 2023–2028
- NIH · Salk Institute for Biological StudiesNot yet scored
Decoding And Targeting The LKB1-AMPK Signaling Pathway In Cancer
Reuben Shaw · $1.1M · 2017–2031